文献速递先天性心脏病外科

当代儿科心脏移植后Fontan患者生存率已改善

Fontan Patient Survival After Pediatric Heart Transplantation Has Improved in the Current Era.
PubMed 文献 · Ann Thorac Surg · 2016-11-15

基于儿科心脏移植研究数据库,比较早期(1993-2006,n=150)与晚期(2007-2014,n=252)Fontan患者心脏移植后生存,晚期生存显著改善(p=0.02),1年生存率从77%升至89%,与晚期非Fontan先心病患者(92%)相近,不应仅因Fontan病史排除移植。

要点

  • Fontan患者心脏移植后生存较早期显著改善,1年生存率77%升至89%。
  • 晚期Fontan患者移植后1年生存率89%,与非Fontan先心病患者92%相近。
  • 仅呼吸机支持与较早移植年份为多因素分析中死亡的显著危险因素。

核心结论

  • 当代Fontan患者心脏移植后生存显著改善,预期生存与其他先心病患者相当,不应仅因Fontan病史排除移植考虑。

研究设计与样本

  • 基于儿科心脏移植研究数据库的回顾性比较,Fontan患者早期(1993-2006,n=150)与晚期(2007-2014,n=252)心脏移植后生存及移植前特征比较,并与非Fontan先心病患者比较。

主要发现

  • 晚期Fontan患者移植时更可能需要正性肌力支持、有蛋白丢失性肠病、生长发育迟缓、距离Fontan手术时间更久,但较少使用呼吸机支持。
  • 多因素分析中仅呼吸机支持和较早移植年份为死亡的显著危险因素。
  • Fontan患者移植后生存从早期到晚期显著改善(p=0.02),尤其早期阶段,1年生存率早期77%、晚期89%。
  • 晚期非Fontan先心病患者移植后1年生存率92%,与Fontan患者相近。

临床怎么用

  • Fontan患者可考虑心脏移植,不应仅因Fontan病史排除。
  • 移植前需评估呼吸机支持等危险因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Historically, patients with a prior Fontan procedure for complex congenital heart disease (CHD) have been considered at higher risk for death after heart transplant (HT) compared with other HT transplant candidates. With the overall trend of improved survival of pediatric HT recipients, it is unclear of Fontan patient post-HT survival has also improved in the current era. METHODS: Data from the Pediatric Heart Transplant Study database for Fontan patients who underwent HT was compared between the early era (1993 to 2006, n = 150) and late era (2007 to 2014, n = 252). Post-HT survival and pre-HT characteristics were compared among eras and also with non-Fontan CHD patients. RESULTS: At time of HT, Fontan patients in the late era were more likely to require inotropic support, have protein-losing enteropathy, have failure to thrive, and be further from time of Fontan, although less likely to be on ventilator support. Only ventilator support and earlier year of HT were significant risk factors for death in the multivariate analysis. Post-HT Fontan patient survival significantly improved from the early to late era (p = 0.02), particularly in the early phase, with 1-year survival of 77% in the early era and 89% in the late era. Late era non-Fontan CHD patient 1-year post-HT survival was similar to Fontan patients at 92%. CONCLUSIONS: Survival of Fontan patients after HT has significantly improved in the current era. Currently, expected post-HT survival for Fontan patients is on par with other CHD patients. Fontan patients should not be excluded from consideration for HT solely on a history of Fontan.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Simpson KE, Pruitt E, Kirklin JK, et al. Fontan Patient Survival After Pediatric Heart Transplantation Has Improved in the Current Era. Ann Thorac Surg. 2016. PMID: 27863728. doi:10.1016/j.athoracsur.2016.08.110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。